SGLT2 INHIBITORS BEYOND DIABETES A RETROSPECTIVE AUDIT OF PRESCRIBING PATTERNS IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
Mehak NazeemMedical Student, Samarkand state medical university, Uzbekistan ,Haleema IqbalMedical Student, Samarkand state medical university UzbekistanNayab NisarMedical Student , Samarkand state medical university, Uzbekistan ,SaifullahMedical Student, Samarkand state medical university, Uzbekistan ,
ABI
Аннотация
Heart failure with preserved ejection fraction (HFpEF) constitutes a substantial and increasing proportion of heart failure cases worldwide, with historically limited evidence-based therapeutic options. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, initially developed for the management of type 2 diabetes mellitus, have demonstrated significant cardiovascular benefits, including reductions in heart failure hospitalizations and improvement in functional outcomes, irrespective of glycemic status. This retrospective audit aimed to evaluate prescribing patterns of SGLT2 inhibitors in patients with HFpEF, with particular emphasis on their utilization beyond diabetes.
Ҳали таржима қилинмаган
Мавзулар
Идентификаторлар
Иқтибослар ва манбалар
0 та иқтибос0 та фойдаланилган манба